Clinical Trial Update: Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA) [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating palbociclib with endocrine therapy in ER-positive/HER2-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Endocrine therapy
• Palbociclib (palbociclib)

Snippet

Sponsor: Jules Bordet Institute | Conditions: Breast Cancer Female | Phase 2 | Status: COMPLETED